Styliani Karanika

9PUBLICATIONS
23CO-AUTHORS
Molecular targetsGene and molecular therapyMedical mycologyMedical bacteriologyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 20, 2026
A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

|Apr 23, 2025
Novel Vaccines Targeting the Highly Conserved SARS-CoV-2 ORF3a Ectodomain Elicit Immunogenicity in Mouse Models.

Jacob Meza, Elizabeth Glass, Avinaash K Sandhu

|Nov 19, 2024
Pharmacologic Inhibition of Macrophage Triglyceride Biosynthesis Pathways Does Not Improve Mycobacterium tuberculosis Control in Infected Mice.

Jennie Ruelas Castillo, Valentina Guerrini, Darla Quijada

|Oct 10, 2024
Targeting CCRL2 enhances therapeutic outcomes in a tuberculosis mouse model.

Tianyin Wang, Darla Quijada, Taha Ahmenda

|Sep 16, 2024
Therapeutic DNA Vaccine Targeting Mycobacterium tuberculosis Persisters Shortens Curative Tuberculosis Treatment.

Styliani Karanika, Tianyin Wang, Addis Yilma

|Sep 16, 2024
MIP3α-Rel Mtb intranasal DNA vaccination induces reactive T-cell infiltration into the lungs in mice and macaques.

James T Gordy, Jean J Zheng, Amanda R Maxwell

Pageof 2

Frequent Collaborators

4 joint publications

Theodoros Karantanos

3 joint publications

Petros C Karakousis

2 joint publications

James T Gordy

2 joint publications

Richard B Markham